专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

11. 发明授权

US08034790B2 Use of MDA-7 to inhibit pathogenic infectious organisms 有权
标题翻译：使用MDA-7抑制致病性感染性生物体
公开(公告)号：US08034790B2
公开(公告)日：2011-10-11
申请号：US11001702
申请日：2004-12-01
申请人： Sunil Chada
发明人： Sunil Chada
IPC分类号： A61K38/20 , A61K48/00
CPC分类号： A61K38/20 , A61K9/0019 , A61K48/00 , C07K14/4748 , Y02A50/473 , Y02A50/475 , Y02A50/478 , Y02A50/479
摘要： Methods of suppressing or preventing an infection of a subject by a pathogen that involve administering to the subject a composition that includes a therapeutically effective amount of an MDA-7 polypeptide or a nucleic acid encoding the MDA-7 polypeptide, and a pharmaceutically acceptable preparation suitable for delivery to the subject, wherein the MDA-7 suppresses or prevents the infection, are disclosed. Also disclosed are methods of suppressing or preventing a viral infection of a cell, including obtaining an MDA-7 polypeptide or a nucleic acid encoding the MDA-7 polypeptide, and contacting the cell with the MDA-7 polypeptide or the nucleic acid encoding the MDA-7 polypeptide, wherein the MDA-7 suppresses or prevents infection of the cell.
摘要翻译：通过病原体抑制或预防受试者感染的方法涉及向受试者施用包含治疗有效量的MDA-7多肽或编码MDA-7多肽的核酸的组合物和适合的药学上可接受的制剂用于递送到受试者，其中MDA-7抑制或预防感染。还公开了抑制或预防细胞病毒感染的方法，包括获得MDA-7多肽或编码MDA-7多肽的核酸，并使细胞与MDA-7多肽或编码MDA的核酸接触 -7多肽，其中MDA-7抑制或预防细胞的感染。

12. 发明申请

US20080292592A1 Oncolytic Adenovirus Armed with Therapeutic Genes 审中-公开
标题翻译：具有治疗基因的溶瘤腺病毒
公开(公告)号：US20080292592A1
公开(公告)日：2008-11-27
申请号：US11568499
申请日：2005-05-02
申请人： Sunil Chada , William Wold , Lou Zumstein
发明人： Sunil Chada , William Wold , Lou Zumstein
IPC分类号： A61K35/76 , C12N7/00 , A61P31/00
CPC分类号： C12N15/86 , A61K35/761 , A61K38/00 , A61K45/06 , C07K14/47 , C07K14/4746 , C12N7/00 , C12N2710/10332 , C12N2710/10343 , C12N2830/008 , A61K2300/00
摘要： The present invention involves compositions and methods for treating preventing cancer using compositions including replication competent adenovirus. The application competent adenovirus may or may not encode a therapeutic polynucleotide.
摘要翻译：本发明涉及使用包括复制感受态腺病毒的组合物治疗预防癌症的组合物和方法。应用感受态腺病毒可以编码或不编码治疗性多核苷酸。

13. 发明授权

US07423015B1 Antihelminthic drugs as a treatment for hyperproliferative diseases 失效
标题翻译：抗血栓药物作为过度增殖性疾病的治疗
公开(公告)号：US07423015B1
公开(公告)日：2008-09-09
申请号：US10043877
申请日：2002-01-09
申请人： Tapas Mukhopadhyay , Sunil Chada , Abner Mhashilkar , Jack A. Roth
发明人： Tapas Mukhopadhyay , Sunil Chada , Abner Mhashilkar , Jack A. Roth
IPC分类号： A01K43/78
CPC分类号： A61K31/4184 , A61K31/4439
摘要： The present invention is directed to the use of benzimidazole derivatives for the treatment of tumors and in combination with tumor suppressor gene therapy. In a particular embodiment, treatment of p53-positive tumors with benzimidazole derivatives induces p53 expression and increases its half-life, resulting in apoptotic death of the tumor cells. Similarly, in conjunction with p53 gene therapy, benzimidazole derivatives induce p53 expression and accumulation in tumor cells regardless of their p53 status. The combination treatment subsequently elicits apoptosis of the tumor cells.
摘要翻译：本发明涉及苯并咪唑衍生物用于治疗肿瘤并与肿瘤抑制基因治疗相结合的用途。在一个具体实施方案中，用苯并咪唑衍生物治疗p53阳性肿瘤诱导p53表达并增加其半衰期，导致肿瘤细胞的凋亡死亡。类似地，结合p53基因治疗，苯并咪唑衍生物诱导肿瘤细胞中的p53表达和积累，而不管其p53状态如何。随后的联合治疗引起肿瘤细胞凋亡。

14. 发明申请

US20070003550A1 P53 vaccines for the treatment of cancers 有权
标题翻译： P53疫苗用于治疗癌症
公开(公告)号：US20070003550A1
公开(公告)日：2007-01-04
申请号：US11433079
申请日：2006-05-12
申请人： Scott Antonia , Dmitry Gabrilovich , Sunil Chada , Kerstin Menander
发明人： Scott Antonia , Dmitry Gabrilovich , Sunil Chada , Kerstin Menander
IPC分类号： A61K39/395
CPC分类号： A61K39/0011 , A61K45/06 , A61K47/6901 , A61K2039/5154 , A61K2039/5158 , A61K2039/53 , A61K2039/572 , A61K2039/585
摘要： The present invention relates to immunotherapy methods for treating hyperproliferative disease in humans, particularly to hyperproliferative disease that is refractory to therapy. More specifically, the invention is directed, in one embodiment, to methods for treating a subject with a hyperproliferative disease in which the expression of a self gene is upregulated in therapy-resistant hyperproliferative cells. In another embodiment, an adenoviral expression construct comprising a self gene under the control of a promoter operable in eukaryotic cells is administered to the therapy-resistant hyperproliferative cells. The present invention thus provides immunotherapies for treating therapy-resistant hyperproliferative disease by attenuating the natural immune system's CTL response against hyperproliferative cells or overexpressing mutant p53 antigens, for example.
摘要翻译：本发明涉及用于治疗人的过度增殖性疾病的免疫治疗方法，特别是治疗难治的过度增殖性疾病。更具体地，在一个实施方案中，本发明涉及治疗具有过度增殖性疾病的受试者的方法，其中自身基因的表达在耐药性过度增殖细胞中上调。在另一个实施方案中，将包含在真核细胞中可操作的启动子控制的自身基因的腺病毒表达构建体施用于耐药性过度增殖细胞。因此，本发明提供了通过减弱例如天然免疫系统对过度增殖细胞或过表达突变型p53抗原的CTL应答来治疗耐药性过度增殖性疾病的免疫疗法。

15. 发明申请

US20060052322A1 Combination treatment of cancer with elicitor of gene product expression and gene-product targeting agent 审中-公开
标题翻译：用基因产物表达诱发剂和基因产物靶向剂联合治疗癌症
公开(公告)号：US20060052322A1
公开(公告)日：2006-03-09
申请号：US11150521
申请日：2005-06-10
申请人： Jack Roth , Guido Schumacher , Sunil Chada
发明人： Jack Roth , Guido Schumacher , Sunil Chada
IPC分类号： A61K48/00
CPC分类号： C12N15/86 , A61K38/1709 , A61K39/39558 , A61K48/00 , A61K2039/505 , C07K16/2863 , C07K2317/24 , C12N2710/10343 , A61K2300/00
摘要： The present invention concerns cancer therapy employing an expression construct that affects regulation of one or more particular nucleic acid sequences that encodes a gene product to which an agent is then targeted. In specific embodiments, the present invention relates to the use of p53 gene therapy to treat cancers in combination with Erbitux™(cetuximab). Viral and non-viral gene delivery systems are disclosed.
摘要翻译：本发明涉及使用影响一种或多种编码基因产物的特定核酸序列的调节的表达构建体的癌症疗法，所述基因产物随后被靶向。在具体实施方案中，本发明涉及p53基因治疗与Erbitux TM（西妥昔单抗）联合治疗癌症的用途。公开了病毒和非病毒基因递送系统。

16. 发明授权

US09402919B2 Vectors conditionally expressing protein 有权
标题翻译：有条件表达蛋白质的载体
公开(公告)号：US09402919B2
公开(公告)日：2016-08-02
申请号：US14001943
申请日：2012-03-02
申请人： Jeremiah F. Roeth , Charles C. Reed , Brandon Cuthbertson , Sunil Chada , William E. Fogler , Fayaz Khazi
发明人： Jeremiah F. Roeth , Charles C. Reed , Brandon Cuthbertson , Sunil Chada , William E. Fogler , Fayaz Khazi
IPC分类号： A61K48/00 , C12N15/86 , C07K14/505 , C07K14/54 , C07K14/56 , C07K14/565 , C07K14/705 , C07K14/47 , C12N15/85
CPC分类号： A61K48/0025 , A61K38/1816 , A61K38/208 , A61K38/212 , A61K48/0066 , A61K48/0075 , C07K14/4713 , C07K14/505 , C07K14/5428 , C07K14/5434 , C07K14/56 , C07K14/565 , C07K14/70567 , C07K2319/70 , C07K2319/715 , C07K2319/81 , C12N15/85 , C12N15/86 , C12N2710/10343 , C12N2750/14143 , C12N2830/002 , C12N2830/75 , C12N2830/85 , C12N2840/203
摘要： This invention relates to the field of therapeutics. Disclosed are methods of conditionally expressing erythropoietin under the control of an ecdysone receptor-based gene expression modulation system in the presence of activating ligand and uses for therapeutic purposes in animals. The methods of the invention cause an in vivo increase in the expression of erythropoietin and an increase in the hematocrit or volume percentage of red blood cells in blood after administration of the ligand.
摘要翻译：本发明涉及治疗领域。公开了在活化配体的存在下在基于蜕皮激素受体的基因表达调节系统的控制下有条件地表达促红细胞生成素的方法和用于动物中的治疗目的的方法。本发明的方法导致体内增加促红细胞生成素的表达，并且在给予配体后血液中红血细胞的血细胞比容或体积百分数增加。

17. 发明申请

US20070231304A1 PROGNOSTIC FACTORS FOR ANTI-HYPERPROLIFERATIVE DISEASE GENE THERAPY 审中-公开
标题翻译：抗高血压病基因治疗的预防因素
公开(公告)号：US20070231304A1
公开(公告)日：2007-10-04
申请号：US11668981
申请日：2007-01-30
申请人： Robert Sobol , Sunil Chada , Louis Zumstein , Esteban Cvitkovic , Kerstin Menander
发明人： Robert Sobol , Sunil Chada , Louis Zumstein , Esteban Cvitkovic , Kerstin Menander
IPC分类号： A61K48/00 , A61K31/7105 , A61P43/00 , C12Q1/68 , A61K31/711
CPC分类号： G01N33/5011 , A61K31/00 , A61K31/7105 , A61K31/711 , A61K38/1709 , A61K48/005 , C12N15/86 , C12N2710/10343 , C12Q1/6886 , C12Q2600/106 , G01N33/502
摘要： The present invention relates to the identification of various prognostic factors that predict response in patients with hyperproliferative disease such as cancer to gene therapy, and their use in methods of treating such patients with an anti-hyperproliferative disease gene therapy. Also described are methods of treatment for Li Fraumeni syndrome, and for assessing anti-cancer gene therapy using PET scans.
摘要翻译：本发明涉及预测癌症与基因治疗等过度增殖性疾病患者反应的各种预后因素的鉴定及其在抗过度增殖性疾病基因治疗方法中的应用。还描述了Li Fraumeni综合征的治疗方法和用于使用PET扫描来评估抗癌基因治疗的方法。

18. 发明申请

US20060134801A1 Methods and compositions involving MDA-7 审中-公开
标题翻译：涉及MDA-7的方法和成分
公开(公告)号：US20060134801A1
公开(公告)日：2006-06-22
申请号：US10791692
申请日：2004-03-02
申请人： Sunil Chada , John Mumm , Rajagopal Ramesh , Abner Mhashilkar , Raymond Meyn , Elizabeth Grimm
发明人： Sunil Chada , John Mumm , Rajagopal Ramesh , Abner Mhashilkar , Raymond Meyn , Elizabeth Grimm
IPC分类号： G01N1/10
CPC分类号： C07K14/47 , A61K38/00 , Y10T436/25375
摘要： The present invention relates to compositions and methods involving MDA-7. More specifically, the present invention is directed to diagnostic, prognostic, and therapeutic treatment compositions and methods for treatment of cancer and other angiogenesis-related disorders (anti-angiogenesis therapy). The present invention is also directed to methods of purification of MDA-7.
摘要翻译：本发明涉及涉及MDA-7的组合物和方法。更具体地，本发明涉及用于治疗癌症和其它血管发生相关病症（抗血管生成治疗）的诊断，预后和治疗治疗组合物和方法。本发明还涉及MDA-7的纯化方法。

19. 发明申请

US20050171045A1 Dendritic cells transduced with a wild-type self gene elicit potent antitumor immune responses 审中-公开
标题翻译：用野生型自身基因转导的树突状细胞引起有效的抗肿瘤免疫应答
公开(公告)号：US20050171045A1
公开(公告)日：2005-08-04
申请号：US11025796
申请日：2004-12-29
申请人： Dmitry Gabrilovich , David Carbone , Sunil Chada , Abner Mhashilkar
发明人： Dmitry Gabrilovich , David Carbone , Sunil Chada , Abner Mhashilkar
IPC分类号： A61K39/00 , A61K48/00 , C12N15/85 , C12Q1/68
CPC分类号： C12N15/86 , A61K39/0011 , A61K2039/5154 , A61K2039/5156 , A61K2039/53 , A61K2039/54 , C12N2710/10343
摘要： The present invention relates to immunotherapy methods for treating hyperproliferative disease or pathogen-induced diseases in humans. More specifically, the invention is directed, in one embodiment, to methods for treating a subject with a hyperproliferative disease in which the expression of a self gene is upregulated in hyperproliferative cells. In another embodiment, an adenoviral expression construct comprising a self gene under the control of a promoter operable in eukaryotic cells is intradermally administered to said hyperproliferative cells. In another embodiment of the present invention, a pathogen-induced disease in which the pathogen gene expression is increaed or altered, is treated by intradermally administered a pathogen gene under the control of a promoter operable in eukaryotic cells. The present invention thus provides immunotherapies for treating hyperproliferative and pathogen diseases by attenuating the natural immune systems CTL response against hyperproliferative cells or overexpressing mutant p53 antigens.
摘要翻译：本发明涉及用于治疗人的过度增殖性疾病或病原体诱发的疾病的免疫治疗方法。更具体地，在一个实施方案中，本发明涉及用过度增殖性疾病治疗受试者的方法，其中自身基因的表达在过度增殖细胞中上调。在另一个实施方案中，包含在真核细胞中可操作的启动子控制下的自身基因的腺病毒表达构建体被皮内施用于所述过度增殖细胞。在本发明的另一个实施方案中，病原体诱导的病原体基因表达增加或改变的疾病通过在可真核细胞中可操作的启动子的真皮内施用病原体基因进行治疗。因此，本发明提供了通过减弱天然免疫系统CTL对抗过度增殖细胞或过表达突变型p53抗原来治疗过度增殖和病原体疾病的免疫疗法。

20. 发明授权

US5736388A Bacteriophage-mediated gene transfer systems capable of transfecting eukaryotic cells 失效
标题翻译：能够转染真核细胞的噬菌体介导的基因转移系统
公开(公告)号：US5736388A
公开(公告)日：1998-04-07
申请号：US366522
申请日：1994-12-30
申请人： Sunil Chada , Thomas W. Dubensky, Jr.
发明人： Sunil Chada , Thomas W. Dubensky, Jr.
IPC分类号： A61K48/00 , C07K14/01 , C12N7/00 , C12N7/01 , C12N15/866 , C12N15/87 , C12N15/85 , C12N15/88
CPC分类号： C12N15/86 , C07K14/005 , C12N15/87 , C12N7/00 , A61K48/00 , C12N2795/10322 , C12N2795/10343 , C12N2800/202
摘要： Lamboid bacteriophage capable of specifically interacting with and delivering nucleic acid molecules to eukaryotic cells are disclosed. Such bacteriophage-derived gene transfer systems target one or more specific receptors on eukaryotic cells, for instance by incorporating mutant tail fiber proteins or by incorporating known ligands for specific eukaryotic receptors into lambda phage. Also disclosed are methods for identifying and producing modified bacteriophage tail fiber polypeptides capable of specifically interacting with eukaryotic transmembrane proteins. Methods of treating diseases using such gene transfer systems are also disclosed.
摘要翻译：公开了能够与真核细胞特异性相互作用并递送核酸分子的id噬噬菌体。这样的噬菌体衍生的基因转移系统靶向真核细胞上的一种或多种特异性受体，例如通过掺入突变型尾纤维蛋白或通过将已知的特异性真核受体配体掺入λ噬菌体中。还公开了用于鉴定和产生能够与真核跨膜蛋白特异性相互作用的修饰的噬菌体尾纤维多肽的方法。还公开了使用这种基因转移系统治疗疾病的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式